I don't know why the company hasn't mentioned it, but the PXS orbital inhaler (a one-and-done disposable inhaler that delivers a high payload of inhaled antibiotics) is to be trialed for tuberculosis in partnership with the Woolcock Institute (they have previously mentioned this partnership with Woolcock but only in relation to CF).
Tuburculosis effects 14 million people each year and there are 1.4 million deaths. This could be something to watch and yet another high value discovery asset in the PXS pipeline.
Pretty high quality presentation about it on YouTube (date 10 June 2014):
I don't know why the company hasn't mentioned it, but the PXS...
Add SNT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
3.3¢ |
Change
-0.001(2.94%) |
Mkt cap ! $42.58M | |||
| Open | High | Low | Value | Volume |
| 3.3¢ | 3.3¢ | 3.3¢ | $6.417K | 194.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 106747 | 3.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 3.3¢ | 228097 | 1 |
View Market Depth
| Last trade - 16.10pm 17/09/2024 (20 minute delay) ? |
| SNT (ASX) Chart |